<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968054</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0189</org_study_id>
    <nct_id>NCT04968054</nct_id>
  </id_info>
  <brief_title>Comparison of IONM Between Remimazolam and Propofol</brief_title>
  <official_title>Comparison of Intraoperative Neurophysiological Monitoring According to the Use of Anesthetics During Total Intravenous Anesthesia in Spine Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhalation anesthetics significantly can delay latency and reduce amplitude of cortical MEPs&#xD;
      and SSEPs signals compared to intravenous anesthetics by acting on not only GABA&#xD;
      (Î³-aminobutyric acid) receptors but also NMDA (N-methyl-D-aspartate) receptors, so total&#xD;
      intravenous anesthesia (TIVA) have been more preferred for neurophysiological monitoring&#xD;
      follow-up during surgery. However, just less than inhalation anesthetics, the decrease of&#xD;
      amplitude and the delay of latency also occur according to the dose dependant of propofol.&#xD;
      Moreover, it can cause various adverse effects such as delayed recovery after anesthesia or&#xD;
      propofol infusion syndrome, consequently, combined methods with other agents or conversion to&#xD;
      other relative anesthetics are being made. Remimazolam is a ultra-short-acting&#xD;
      benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in&#xD;
      plasma and not accumulates in the body for long periods of infusion or even with high dose&#xD;
      administration. Recently, there have been repored that continuous infusion of 0.5-1.5 mg/kg&#xD;
      of remimazolam has little effect on the motor evoked potential (MEPs) of cervical spine&#xD;
      surgery patients, but this is a case report without the control group; further prospective&#xD;
      studies are definitely needed. Therefore, in the case of using propofol or remimazolam for&#xD;
      total intravenous anesthesia, we aim to investigate which intravenous anesthetic is more&#xD;
      appropriate for intraoperative neurophysiological monitoring by comparing the results of the&#xD;
      somatosensory evoked potential (SSEPs) and MEPs according to these anesthetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Latency of SSEPs</measure>
    <time_frame>At the 30 minutes after anesthetic induction (before surgical incision)</time_frame>
    <description>The difference of SSEPs between the two groups (propofol vs. remimazolam) compared with baseline SSEPs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Ossification Posterior Longitudinal Ligament</condition>
  <condition>Cervical Spondylotic Myelopathy</condition>
  <arm_group>
    <arm_group_label>Propofol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm I (Propofol)</intervention_name>
    <description>Propofol group will be inducted and maintained total intravenous anesthesia with propofol 2% and remifentanil under Shinider and Minto target controlled infusion (TCI) model, respevtively.</description>
    <arm_group_label>Propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm II (Remimazolam)</intervention_name>
    <description>Remimazolam group started total intravenous anesthesia with remiamazolam at 6 mg/kg/h at the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.</description>
    <arm_group_label>Remimazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients who aged 20-70 years with ASA-PS 1-3, diagnosed of ossification of the&#xD;
             posterior longitudinal ligament or cervical spondylotic myelopathy, in need of&#xD;
             intraoperative neurophysiological monitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tolerance or hypersensitivity to benzodiazepine or propofol&#xD;
&#xD;
          -  Dependence or addiction to psychotropic drugs or alcohol&#xD;
&#xD;
          -  Previous brain-related neurosurgery&#xD;
&#xD;
          -  Inserted status of pacemaker&#xD;
&#xD;
          -  Inserted status of intracranial device&#xD;
&#xD;
          -  Steroids use during surgery&#xD;
&#xD;
          -  Pregnant women, subjects who lack the ability to make decisions and susceptible to&#xD;
             voluntary participation decisions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Woo Han</last_name>
      <phone>82-2-20194601</phone>
      <email>HANESTH@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Dong Woo Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

